Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate

Ovid Therapeutics reported Q4 earnings of $0.06 per share, surpassing the analyst estimate of $(0.11) by 152.63%, and showing a significant improvement from a loss of $(0.13) per share in the same quarter last year. The company's quarterly sales reached $718,000, exceeding the estimate of $13,333 by 5,290%, and marking an 844.74% increase from $76,000 in the previous year.